A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).
R. M. Connolly
No relevant relationships to disclose
M. A. Rudek
No relevant relationships to disclose
H. L. Mc Leod
No relevant relationships to disclose
E. Garrett-Mayer
No relevant relationships to disclose
S. C. Jeter
No relevant relationships to disclose
L. A. Wright
No relevant relationships to disclose
V. Stearns
No relevant relationships to disclose
D. K. Armstrong
No relevant relationships to disclose
J. H. Fetting
No relevant relationships to disclose
S. P. Watkins
No relevant relationships to disclose
N. E. Davidson
No relevant relationships to disclose
A. C. Wolff
Research Funding - Genentech; Roche